IL6 Cancer Research Results

IL6, Interleukin-6: Click to Expand ⟱
Source: HalifaxProj(inhibit)
Type:
Interleukin-6 (IL-6) is a cytokine that plays a significant role in inflammation and the immune response. It is produced by various cell types, including T cells, B cells, macrophages, and fibroblasts.
IL-6 can promote tumor cell proliferation and survival. Many cancer cells produce IL-6, which can create an autocrine loop that supports their growth.
IL-6 is a high-value inflammatory biomarker in cancer, reporting cytokine burden, catabolic stress, and STAT3-linked survival signaling. While not tumor-specific, elevated and rising IL-6 strongly predicts poor prognosis and limited treatment tolerance, making it an important system-state indicator alongside CRP and ferritin.


PC, Pancreatic Cancer: Click to Expand ⟱
Pancreatic Cancer: Hypoxia (low oxygen tension) is commonly found in solid tumors. Hypoxia-inducible factor-1 (HIF-1),is a key mediator of the cellular response to hypoxia and is overexpressed in a wide variety of solid tumors, including pancreatic cancer.
Nanog is highly expressed in CSCs compared to normal cells [93–97]
HIF-1↑
Scientific Papers found: Click to Expand⟱
27- EA,    Ellagic acid inhibits human pancreatic cancer growth in Balb c nude mice
- in-vivo, PC, PANC1
HH↓, Gli1↓, GLI2↓, CDK1/2/5/9↓, p‑Akt↓, NOTCH1↓, Shh↓, Snail↓, E-cadherin↑, NOTCH3↓, HEY1↓, TumCG↓, TumCP↓, Casp3↑, cl‑PARP↑, Bcl-2↓, cycD1/CCND1↓, CDK2↓, CDK6↓, BAX↑, COX2↓, Hif1a↓, VEGF↓, VEGFR2↓, IL6↓, IL8↓, MMP2↓, MMP9↓, NA↓,
3082- RES,    Resveratrol Ameliorates the Malignant Progression of Pancreatic Cancer by Inhibiting Hypoxia-induced Pancreatic Stellate Cell Activation
- in-vitro, PC, PANC1 - in-vitro, PC, MIA PaCa-2 - in-vivo, NA, NA
VEGF↓, CXCL12↓, IL6↓, α-SMA↓, Hif1a↓, TumCI↓, EMT↓,

Showing Research Papers: 1 to 2 of 2

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 2

Pathway results for Effect on Cancer / Diseased Cells:


NA, unassigned ⓘ

NA↓, 1,  

Cell Death ⓘ

p‑Akt↓, 1,   BAX↑, 1,   Bcl-2↓, 1,   Casp3↑, 1,   HEY1↓, 1,  

DNA Damage & Repair ⓘ

cl‑PARP↑, 1,  

Cell Cycle & Senescence ⓘ

CDK1/2/5/9↓, 1,   CDK2↓, 1,   cycD1/CCND1↓, 1,  

Proliferation, Differentiation & Cell State ⓘ

EMT↓, 1,   Gli1↓, 1,   HH↓, 1,   NOTCH1↓, 1,   NOTCH3↓, 1,   Shh↓, 1,   TumCG↓, 1,  

Migration ⓘ

CXCL12↓, 1,   E-cadherin↑, 1,   GLI2↓, 1,   MMP2↓, 1,   MMP9↓, 1,   Snail↓, 1,   TumCI↓, 1,   TumCP↓, 1,   α-SMA↓, 1,  

Angiogenesis & Vasculature ⓘ

Hif1a↓, 2,   VEGF↓, 2,   VEGFR2↓, 1,  

Immune & Inflammatory Signaling ⓘ

COX2↓, 1,   IL6↓, 2,   IL8↓, 1,  

Hormonal & Nuclear Receptors ⓘ

CDK6↓, 1,  

Clinical Biomarkers ⓘ

IL6↓, 2,  
Total Targets: 34

Pathway results for Effect on Normal Cells:


Total Targets: 0

Scientific Paper Hit Count for: IL6, Interleukin-6
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:21  Cells:%  prod#:%  Target#:158  State#:%  Dir#:1
  wNotes=0  sortOrder:rid,rpid

 

Home Page